Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7020025 | 0.85 | CA12 (0.38) | CA12CA14AAK1DGAT1 | |
| SCHEMBL13682813 | 0.85 | CA12 (0.38) | CA12CA14AAK1DGAT1 | |
| SCHEMBL26211162 | 0.83 | MMP13 (0.30) | AAK1 | |
| SCHEMBL25384121 | 0.83 | MMP13 (0.30) | AAK1 | |
| SCHEMBL28334313 | 0.83 | CA12 (0.37) | CA12CA14AAK1DGAT1 | |
| SCHEMBL21816889 | 0.79 | CTSS (0.36) | CA12CA14AAK1DGAT1 | |
| SCHEMBL18796420 | 0.79 | CA14 (0.41) | CA12CA14AAK1DGAT1 | |
| SCHEMBL7021061 | 0.79 | CA14 (0.41) | CA12CA14AAK1DGAT1 | |
| SCHEMBL9455522 | 0.79 | CA14 (0.41) | CA12CA14AAK1DGAT1 | |
| SCHEMBL31228349 | 0.77 | CA14 (0.39) | CA12CA14AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12325701-B2 | YKL-40 inhibitors and their therapeutic | MOLECURE S.A. (PL) | 2025-06-10 | — | — | US | disclosed |
| US-20230278996-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | MOLECURE S.A. (PL) | 2023-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278996-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | CHI3L1, CHI3L2, CHIA | CA12 2508/4885CA14 1281/4885AAK1 1976/4885 |
| US-12325701-B2 | YKL-40 inhibitors and their therapeutic | CHI3L1, CHI3L2, CHIA | CA12 2486/4885CA14 1177/4885AAK1 1876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.